Status:
COMPLETED
Effect of Dobutamine on Hepatic Blood Flow During Goal-directed Hemodynamic Therapy
Lead Sponsor:
University Hospital, Ghent
Conditions:
General Anesthesia
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
Maintaining adequate perfusion pressure and oxygen supply is essential for organ survival. Splanchnic hypoperfusion during the perioperative period in abdominal surgery may result in mucosal ischemia ...
Detailed Description
All patients receive standardized anesthesia care for pancreaticoduodenectomy according to the existing departmental protocol for these interventions. All patients receive individualized goal-directe...
Eligibility Criteria
Inclusion
- Adult ≥ 18 years ≤ 80 years (female or male).
- ASA I - II - III.
- Able to comprehend, sign and date the written informed consent document to participate in the clinical trial.
- Patient is scheduled for pancreaticoduodenectomy (Whipple's procedure).
Exclusion
- Allergy to the medication dobutamine.
- Renal insufficiency (SCr \> 2 mg/dL).
- Severe heart failure (EF \< 25%).
- Hemodynamic unstable patients.
- Atrial fibrillation.
- Sinus tachycardia \> 100 bpm on pre-operative electrocardiogram.
- Sepsis.
- BMI \> 40.
- Severe coagulopathy (INR \> 2).
- Thrombocytopenia (\< 80 x 103 /mcL).
- End stage liver disease and/or portal hypertension.
- Pregnancy and breastfeeding women.
Key Trial Info
Start Date :
September 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 25 2023
Estimated Enrollment :
58 Patients enrolled
Trial Details
Trial ID
NCT04893655
Start Date
September 14 2021
End Date
July 25 2023
Last Update
August 1 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ghent University Hospital
Ghent, Belgium, 9000